A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line tre... by Talbot, D, Blackhall, F, Kowalski, D, Ramlau, R, Bepler, G, Grossi, F, Lerchenmuller, C, Pinder, M, Mezger, J, Danson, S, Callies, S, Andre, V, Das, M, Lahn, M, Natale, R

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients... by Natale, R, Blackhall, F, Kowalski, D, Ramlau, R, Bepler, G, Grossi, F, Lerchenmüller, C, Pinder-Schenck, M, Mezger, J, Danson, S, Gadgeel, S, Summers, Y, Callies, S, André, V, Das, M, Lahn, M, Talbot, D